When my friend and colleague David Nutt called upon me to become the North American editor for the Journal of Psychopharmacology, I was honoured that he deemed me worthy of this task. I believe that Dr Nutt is one of the brightest psychopharmacologists around, with great clinical experience and a profound knowledge of neuroscience. Being the main editor for a scientific journal is a time-consuming duty, and can be a daunting responsibility. I will certainly do my best to support him from the other side of the Atlantic. I foresee a fruitful collaboration, which should result in drawing an increasing number of high-quality basic science and clinical submissions. Dr Nutt and myself have presented in the same symposia and served together on several Advisory Boards. Our views on current and critical issues in psychopharmacology are quite congruent and I anticipate experiencing the same harmonious collaboration with the Editorial Board.
In brief, I will sumarize the experience and knowledge that I bring as the new North American editor of this Journal. Since 1978, when I started carrying out research in psychopharmacology, my endeavours have focused on elucidating the mechanisms of action of antidepressant and anxiolytic treatments, using mostly electrophysiological techniques in vivo. Anaesthetized rats have mainly been used but, since the mid 1990s, the development of mutant mice has helped better establish the role of various elements controlling the serotonin system, again using intact brains so as not to alter the integrity of important neural circuits. Initially, this work centred on demonstrating that all types of antidepressant at least share the property of enhancing serotonin transmission. More recently, my work has focused on interactions between the serotonin and the norepinephrine systems, to gain a more thorough understanding of how the antidepressant response manifests itself. In the last 10 years, I have strived to extrapolate my laboratory work to the clinical setting by carrying out proof-of-concept studies: our goal is to get depressed patients better, faster. This work has also provided us with an increasing understanding of the mechanisms by which selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic role in obsessive-compulsive disorder. Based on this work, novel targets have been identified to help obtain agents other than SSRIs for treatment of this disorder, some of which are already being tested. Of relevance to my new involvement with this Journal, I am also on the editorial board of the official journals of the Society for Biological Psychiatry, and the Canadian, American, European and International Colleges of Neuropsychopharmacology.
After perusing the 2003 issues of this Journal, I was impressed by the number of interesting papers and deplored the fact that the journal is not more widely read or distributed in North America. In this age, when new journals are popping up like tulips in the spring, it is indeed difficult to increase the visibility of journals with an impact factor in the medium range. Certainly, a key aid in this respect is to provide prompt reviews. I pride myself in rapidly turning around submissions sent to me for appraisal. In fact, if only my papers were evaluated at the rate of my slowest reviews, I would be delighted! I hope that colleagues who called upon me to review papers for their journal will return the favour when I will solicit their help with respect to papers submitted to the Journal of Psychopharmacology.
I plan to explore several strategies with Dr Nutt to help further improve the quality and visibility of the Journal. These may include the publication of review articles based on symposia with distinguished presenters. Selecting such a symposium from the high calibre annual meeting of the British Association of Psychopharmacology may help facilitate this task. In closing, I hope to use my experience as a basic researcher, and my 12 years as a clinician in Canada and the last 4 years in the USA, to bring a North American perspective to the current issues in psychopharmacology that are being discussed in this Journal. I thus look forward to this 'nouveau défi'.
